deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04456517

Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy (REACT)

REACT Trial: A Randomized, Double Blind, Placebo-controlled, Crossover Study of Ranolazine for the Treatment of Crohn's Disease-associated Diarrhea

Sponsor: Vanderbilt University Medical Center

Conditions Crohn's Disease Inflammatory Bowel Disease
Interventions Placebo Ranolazine
Updated 17 times since 2020 Last updated: Jan 14, 2025 Started: Oct 18, 2022 Primary completion: Apr 11, 2024 Completion: Apr 11, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual and subject engagement

Other terminated trials from Vanderbilt University Medical Center

See all terminations from Vanderbilt University Medical Center

Other Crohn's Disease trials with similar outcome

Browse all Crohn's Disease trials

Listed as NCT04456517, this PHASE2 trial focuses on Crohn's Disease and Inflammatory Bowel Disease and remains terminated or withdrawn. Sponsored by Vanderbilt University Medical Center, it has been updated 17 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Dec 2023 · 13 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – present · 18 months · monthly snapshot

Change History

17 versions recorded

  1. Mar 2025 — Present [monthly]

    Terminated PHASE2

  2. Dec 2024 — Mar 2025 [monthly]

    Terminated PHASE2

    Status: Enrolling By Invitation → Terminated

  3. Sep 2024 — Dec 2024 [monthly]

    Enrolling By Invitation PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Enrolling By Invitation PHASE2

  5. Dec 2023 — Jul 2024 [monthly]

    Enrolling By Invitation PHASE2

▶ Show 12 earlier versions

  1. Nov 2022 — Dec 2023 [monthly]

    Enrolling By Invitation PHASE2

  2. Jun 2022 — Nov 2022 [monthly]

    Enrolling By Invitation PHASE2

  3. May 2022 — Jun 2022 [monthly]

    Enrolling By Invitation PHASE2

  4. Feb 2022 — May 2022 [monthly]

    Enrolling By Invitation PHASE2

  5. Jan 2022 — Feb 2022 [monthly]

    Enrolling By Invitation PHASE2

  6. Oct 2021 — Jan 2022 [monthly]

    Enrolling By Invitation PHASE2

  7. Sep 2021 — Oct 2021 [monthly]

    Enrolling By Invitation PHASE2

  8. Jun 2021 — Sep 2021 [monthly]

    Enrolling By Invitation PHASE2

    Status: Not Yet Recruiting → Enrolling By Invitation

  9. Mar 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE2

  10. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE2

  11. Oct 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  12. Aug 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vanderbilt University Medical Center
Data source: Vanderbilt University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations